Bio

EVQLV and Libera Bio are collaborating to develop and deliver new antibodies for intracellular cancer targets

EVQLV Inc. and Libera Bio SL have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent unmet medical needs. Antibodies can be designed to engage very specific targets along cancer pathways A lots of the best validated intracellular targets for cancer are considered “untreatable” because large …

EVQLV and Libera Bio are collaborating to develop and deliver new antibodies for intracellular cancer targets Read More »

Pepromene Bio, Inc. announced a complete response in the first patient treated in the phase 1 B-cell non-Hodgkin’s lymphoma (B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) at City of Hope

IRVINE, California, December 20, 2022 /CNW/ — PeproMene Bio, Inc., a clinical biotechnology company developing novel therapies for the treatment of cancer and immune disorders, today announced that the first patient has been treated for stage 1 relapsed or refractory B-cell non-Hodgkin’s lymphoma (r /r B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) achieved a complete …

Pepromene Bio, Inc. announced a complete response in the first patient treated in the phase 1 B-cell non-Hodgkin’s lymphoma (B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) at City of Hope Read More »